FDA warns of fractures with osteoporosis drugs

Oct 13, 2010 By MATTHEW PERRONE , AP Business Writer

(AP) -- Government health officials warned doctors and patients Wednesday about an increased risk of thigh fractures with a widely used group of bone-strengthening drugs.

The said patients taking bisphosphonate drugs such as Fosamax and Boniva appear more likely to suffer a rare type of fracture of the femur. The fractures occurred just below the hip joint and make up less than 1 percent of all femur fractures.

"We know from clinical trials that these drugs do prevent the common osteoporosis fractures," said Dr. Sandra Kweder, FDA's deputy director for new drugs. "The fractures we're talking about today are very unusual and rare."

In more than half the cases reported to the FDA, patients experienced pain or aching of the groin before the fracture.

It's unclear whether the drugs directly trigger the problem, but the FDA said it is updating the drugs' labels about the potential risk.

work by slowing the loss of that lead to . in that class include Merck & Co.'s Fosamax and Roche's Boniva, as well as Procter & Gamble Co.'s Actonel, Warner Chilcott's Atelvia and Novartis' Reclast.

More than 5 million prescriptions for the drugs were written last year, according to the FDA. The drug is mainly prescribed to women after menopause.

The FDA says patients should continue taking the treatments unless directed to stop by their doctor.

The fractures were publicized in a report last month from the American Society of Bone and Mineral Research, which suggests several explanations for the fractures. One is that the slowdown in cell turnover seen with bisphosphonates could lead to weaker bones in some cases.

The FDA said the fractures "may be related to the use of bisphosphonates for longer than five years." In reviewing reports of , FDA officials said they found patients who had been taking the drugs up to 15 years.

There are no guidelines for how long patients should take the drugs.

Explore further: Medical charity accuses US of pushing India to ease patent rules

5 /5 (1 vote)
add to favorites email to friend print save as pdf

Related Stories

Popular osteoporosis drugs triple risk of bone necrosis

Jan 15, 2008

A University of British Columbia and Vancouver Coastal Health Research Institute study has found that a popular class of osteoporosis drugs nearly triples the risk of developing bone necrosis, a condition that can lead to ...

Once-a-year drug reduces fractures from osteoporosis

May 02, 2007

A treatment for osteoporosis delivered once a year is as effective as current monthly or weekly osteoporosis regimens at reducing the incidence of bone fractures, according to a new study led by a UCSF research team.

Recommended for you

Ebola vaccine not before late 2016: GSK researcher

Oct 17, 2014

An Ebola vaccine by British pharmaceuticals giant GlaxoSmithKline may not be ready for commercial use until late 2016 and should therefore not be seen as the "primary answer" to the current outbreak, a company researcher ...

Chimerix gets FDA OK to test drug for Ebola

Oct 17, 2014

(AP)—A North Carolina drugmaker plans to test its experimental antiviral drug in patients who have Ebola, after getting authorization from regulators at the Food and Drug Administration.

Esbriet, ofev approved to treat deadly lung disease

Oct 16, 2014

(HealthDay)—Two new drugs have been approved by the U.S. Food and Drug Administration to treat progressive lung scarring from an uncertain cause, medically called idiopathic pulmonary fibrosis (IPF).

FDA weighs removing bolded warning from Chantix

Oct 14, 2014

(AP)—The Food and Drug Administration will ask a panel of experts later this week whether a bold-letter warning on the anti-smoking drug Chantix should be removed based on company-supported evidence that the drug does not ...

Drug-coated balloon catheter approved

Oct 13, 2014

(HealthDay)—The first drug-coated balloon catheter designed to clear narrowed or blocked arteries in the thigh and knee has been approved by the U.S. Food and Drug Administration.

User comments : 0